Last reviewed · How we verify
Standard anti-tumor treatment
This drug targets cancer cells by inhibiting cell growth and inducing apoptosis.
This drug targets cancer cells by inhibiting cell growth and inducing apoptosis. Used for Metastatic non-small cell lung cancer, Metastatic colorectal cancer.
At a glance
| Generic name | Standard anti-tumor treatment |
|---|---|
| Sponsor | Qinghai Red Cross Hospital |
| Drug class | anti-tumor treatment |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The exact molecular target is unknown, but it is believed to work by disrupting the cell cycle and promoting programmed cell death. This leads to a reduction in tumor size and an improvement in patient outcomes.
Approved indications
- Metastatic non-small cell lung cancer
- Metastatic colorectal cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer (PHASE2)
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
- Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation (PHASE2)
- Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard anti-tumor treatment CI brief — competitive landscape report
- Standard anti-tumor treatment updates RSS · CI watch RSS
- Qinghai Red Cross Hospital portfolio CI